US2016371466A1PendingUtilityA1
Integrated method for collection and maintenance of detectability of a plurality of microbiological agents in a single clinical sample and for handling a plurality of samples for reporting a sum of diagnostic results for each sample
Assignee: MEDICAL DIAGNOSTIC LABORATORIES LLCPriority: Feb 10, 2005Filed: Aug 31, 2016Published: Dec 22, 2016
Est. expiryFeb 10, 2025(expired)· nominal 20-yr term from priority
G01N 33/569C12Q 1/705C12Q 1/689G16H 10/20C12Q 1/04C12Q 1/045C12Q 1/6895G16H 10/40C12Q 1/6893G06F 19/366
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method and kit related thereto are described for the collection and maintenance of detectability of a plurality of species of microbiological agents in a single clinical sample as well as an integral method for handling a plurality of the samples and managing information associated therewith for reporting a sum of diagnostic results for each sample.
Claims
exact text as granted — not AI-modified1 . A method for the collection and maintenance of detectability of a plurality of species of microbiological agents selected from the group consisting of bacteria, fungi, and viruses, in a primary gynecological sample and for handling a plurality of primary gynecological samples and managing information associated therewith for reporting a sum of diagnostic results for each primary gynecological sample, comprising the steps of:
(a) collecting a primary gynecological sample from a patient, (b) providing a transport medium in a resealable container with instructions for preparation and handling of said primary gynecological sample and an indication of the detectability of the plurality of species contained in said primary gynecological sample,
wherein said transport medium is BD Cellmatics Viral Transport Medium®;
(c) adding said primary gynecological sample to said transport medium,
wherein said transport medium supports viability of said plurality of species of microbiological agents sustained at room temperature for at least 48 hours and up to 5 days;
(d) receiving a plurality of said primary gynecological samples in step (c), each primary gynecological sample having identity and a test requisition form containing information associated therewith,
wherein said information indicates a test for at least one species from a plurality of species;
(e) entering said information into a system to create a requisition file for each primary gynecological sample; (f) processing said information to create a list of each primary gynecological sample to be tested for each species; (g) dispensing an aliquot corresponding to each primary gynecological sample into an individual vessel, to create a secondary gynecological sample, for each designated test for different species on each secondary gynecological sample; (h) assembling a general supply of master reagent mix for each different test; (i) combining an aliquot of master reagent mix for each test with each corresponding secondary gynecological sample to produce a diagnostic test reaction for each secondary gynecological sample; (j) determining the presence or absence of a certain product of each reaction to produce a result, recording said result of each reaction; (k) combining said result of each reaction derived from each primary gynecological sample into the requisition file for each primary gynecological sample on the system, thereby producing a sum of results for each primary gynecological sample; and (l) reporting said sum of results to an attending physician who ordered the test within 24-48 hours after receipt of said primary gynecological sample in step (d),
wherein the plurality of species comprises at least one species selected from the group consisting of Molluscum contagiosum virus, Mycoplasma genitalium, Mycoplasma hominis, Candida dubliniensis, Candida krusei, Candida lusitaneae, Atopobium vaginae , erythromycin-resistant Streptococcus agalactiae , clindamycin-resistant Streptococcus agalactiae, Lymphogranuloma venereum , HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-66, HPV-68, HPV-6/11, HPV-42, HPV-43, and HPV-44.
2 . The method according to claim 1 wherein at least one species within the plurality of species is indicative of at least one gynecological disorder.
3 . The method according to claim 2 wherein at least one (1) species of the plurality of species is selected from the group consisting of Gardnerella vaginalis, Molluscum contagiosum Virus, Mycoplasma genitalium , and Mycoplasma hominis.
4 . A method for the collection and maintenance of detectability of a plurality of species of microbiological agents selected from the group consisting of bacteria, fungi, and viruses, in a primary gynecological sample and for handling a plurality of primary gynecological samples and managing information associated therewith for reporting a sum of diagnostic results for each primary gynecological sample, comprising the steps of:
(a) providing a kit comprised of a transport medium in a resealable container, a sterile swab, and instructions for preparation and handling of a primary gynecological sample and a writing which indicates the detectability of the plurality of species,
wherein said transport medium is BD Cellmatics Viral Transport Medium®, and
wherein viability of said plurality of species of microbiological agents is sustained at room temperature for at least 48 hours and up to 5 days;
(b) adding a collected primary gynecological sample to said transport medium in said kit, wherein said transport medium supports viability of said plurality of species of microbiological agents sustained at room temperature for at least 48 hours and up to 5 days; (c) receiving a plurality of said primary gynecological sample in said transport medium, each such sample being derived from a kit as recited in (a), having identity and a test requisition form containing information associated therewith,
wherein said test requisition information indicates a test for at least one species from the plurality of species;
(d) entering said information into a system to create a requisition file for each primary gynecological sample; (e) processing said information to create a list of primary gynecological samples to be tested for each species; (f) dispensing an aliquot corresponding to each primary gynecological sample into an individual vessel, to create a secondary gynecological sample, for each designated test for different species on each gynecological sample; (g) assembling a general supply of master reagent mix for each different test; (h) combining an aliquot of master reagent mix for each test with each corresponding secondary gynecological sample to produce a diagnostic test reaction for each secondary gynecological sample; (i) determining the presence or absence of a certain product of each reaction to produce a result, recording the result of each reaction; (j) combining the result of each reaction derived from each primary gynecological sample into the requisition file for each gynecological sample on the system, thereby producing a sum of results for each primary gynecological sample; and (k) reporting the results to an attending physician who ordered the test within 24-48 hours after receipt of said primary gynecological sample in step (c),
wherein the plurality of species comprises at least one species selected from the group consisting of Molluscum contagiosum virus, Mycoplasma genitalium, Mycoplasma hominis, Candida dubliniensis, Candida krusei, Candida lusitaneae, Atopobium vaginae , erythromycin-resistant Streptococcus agalactiae , clindamycin-resistant Streptococcus agalactiae, Lymphogranuloma venereum , HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-66, HPV-68, HPV-6/11, HPV-42, HPV-43, and HPV-44.
5 . The method according to claim 4 wherein the presence or absence of a product of at least one reaction is electronically recorded by means of the system.
6 . The method according to claim 4 wherein at least one diagnostic test reaction comprises a real-time Polymerase Chain Reaction (PCR).
7 . The method according to claim 4 wherein the results are reported within about fifty (50) twenty four (24) hours of receiving the sample.
8 . The method according to claim 4 wherein the results are reported within about thirty (30) hours of receiving the sample.
9 . The method according to claim 4 which comprises pyrosequencing.
10 . A method for the collection and maintenance of detectability of a plurality of species of microbiological agents of bacteria, in a primary gynecological sample and for handling a plurality of primary gynecological samples and managing information associated therewith for reporting a sum of diagnostic results for each primary gynecological sample, comprising the steps of:
(a) providing a transport medium in a resealable container with instructions for preparation and handling of a primary gynecological sample and an indication of the detectability of the plurality of species,
wherein said transport medium is BD Cellmatics Viral Transport Medium®, and
wherein viability of said plurality of species of microbiological agents is
sustained at room temperature for at least 48 hours and up to 5 days;
(b) receiving a plurality of said primary gynecological samples, each primary gynecological sample having identity and a test requisition form containing information associated therewith,
wherein the test requisition information indicates a test for at least one species from a plurality of species;
(c) entering the information into a system to create a requisition file for each primary gynecological sample; (d) processing the information to create a list of each primary gynecological samples to be tested for each species; (e) dispensing an aliquot corresponding to each primary gynecological sample into an individual vessel, to create a secondary gynecological sample, for each designated test for different species on each secondary gynecological sample; (f) assembling a general supply of master reagent mix for each different test; (g) combining an aliquot of master reagent mix for each test with each corresponding secondary gynecological sample to produce a diagnostic test reaction for each secondary gynecological sample; (h) determining the presence or absence of a certain product of each reaction to produce a result, recording the result of each reaction; (i) combining the result of each reaction derived from each primary gynecological sample into the requisition file for each primary gynecological sample on the system, thereby producing a sum of results for each primary gynecological sample; and reporting the results to an attending physician who ordered the test within 24-48 hours after receipt of said primary gynecological sample in step (b)
wherein the plurality of species comprises at least one species selected from the group consisting of Atopobium vaginae , erythromycin-resistant Streptococcus agalactiae , clindamycin-resistant Streptococcus agalactiae.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.